: iStockAnalyst.com Symbols Feed

The Week In Review: Biopharma News Back In The Forefront

Sun, 23 Nov 2008 16:19:00 GMT

ChinaBio® Accelerator will hold the ChinaBio® Partnering Forum on June 3 and 4, 2009 in Shanghai; Chiral Quest raised $13 million in a Series B financing from China-based venture capitalists; GSK and Shenzhen Neptunus Interlong will work towards a JV that develops flu vaccines; BMP Sunstone has acquired rights to the Runchang capsule, a liquid-filled hard capsule; Syneron Medical has established a JV to market its medical aesthetic devices in China; China Medical Technologies has developed two molecular diagnostic kits to detect EFGR abnormalities; big pharma continues to make investments in China; China Medical Technologies released positive Q2 results, Genesis Pharmaceuticals reported that Q1 revenues and earnings climbed significantly; Lotus Pharma said its Q3 net income climbed even though revenues dropped slightly; Sinovac Biotech reported that revenue and profits declined in Q3; and China Shenghuo Pharmareleased its Q3[More...]

Lotus Increases Profit In Q3 While Revenues Drop

Tue, 18 Nov 2008 18:50:00 GMT

Lotus Pharmaceuticals announced that its Q3 net income climbed 45% to $3.2 million, even though revenues dropped slightly in the quarter to $16.6 million. The company earned 7 cents per share, fully diluted, bringing its nine-month eps total to 16 cents. Lotus reported that its revenue mix, when compared to the year-ago quarter, were the reason that earnings increased while revenue stayed flat. More details... Stock Symbol: (OTCBB: LTUS)[More...]

The Week in Review: Earnings and Development

Sun, 24 Aug 2008 00:12:00 GMT

Earnings reports for China biomedical companies continued to be released at a slower pace over the past five days. Lotus Pharma announced its revenues climbed an admirable 51% but net income dropped 27%; Sinobiomed emphasized its pipeline rather than its revenues, which are falling; and China Shenghuo Pharma said it will have to restate its reports because of irregularities; Smith & Nephew will expanding two China manufacturing facilities; CRO Venturepharm Labs purchased 44% of the US CRO, Commonwealth Biotechnologies; and MicuRx Pharma picked its first preclinical development candidate, a next-generation antibiotic. More details... Stock Symbols: (OTCBB: LTUS) (OTCBB: SOBM) (AMEX: KUN) (NYSE: SNN) (HKEX: 8225) (NSDQ: CBTE)[More...]

Lotus Pharma Reports Higher Revenues, Lower Net

Mon, 18 Aug 2008 18:55:00 GMT

Lotus Pharmaceuticals, Inc. released its Q2 financial report, which showed the company followed a theme similar to several other China biopharmas this quarter: revenues are sharply higher, but net income fails to keep pace. In fact, Lotus said its net inc[More...]

The Week in Review: Company Profiles and Drug Advancement

Sun, 03 Aug 2008 17:15:00 GMT

In ChinaBio® Today, we profiled two China biotechs last week. One, Shenogen Pharma Group, won one of the two “Most Promising Company” awards at the recent ChinaBio® Investor Forum, The other profiled company, Beike Biotechnology, provides stem cell treatments for a variety of difficult-to-treat maladies. Bridge Labs announced plans to build a second preclinical facility in China; Lotus Pharma will construct a manufacturing plant in Inner Mongolia; Zhejiang Huahai Pharma will provide finished product, not just APIs, to Merck; Tianyin Pharma was given SFDA approval for a generic version of the statin simvastatin; CompuMed received approval from the SFDA to market its osteoporosis diagnostic software in China; Bayer and Onyx Pharmas were awarded SFDA approval for their cancer drug, Nexavar®; Huifeng Bio-Pharmaceutical remains on track to gain approval[More...]

Lotus Unveils Plans for New Manufacturing Facility

Mon, 28 Jul 2008 18:54:00 GMT

Lotus Pharmaceuticals bought land rights to property in Inner Mongolia on which it will construct a manufacturing facility. Liang Fang Pharmaceutical Company, a China subsidiary of Lotus, paid 108 million RMB ($15.5 million) for the rights, of which 39 mi[More...]

The Week in Review: The China Biopharma Beat

Mon, 26 May 2008 03:24:50 GMT

China Yongxin Pharmaceuticals Inc. completed its previously announced reverse merger with Nutradyne Group; the two China-based minority participants in the Shanghai Schering-Plough JV will put their 45% stake up for sale; Lotus Pharmaceutical...[More...]

Lotus Reports Higher Q1 and New Asthma Drug

Thu, 22 May 2008 19:55:26 GMT

Lotus Pharmaceuticals, Inc. announced a 41% increase in revenues in Q1, though net income was up by a smaller...[More...]

Lotus Private Placement Includes Make Good Clause

Tue, 26 Feb 2008 18:44:12 GMT

Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) raised $5 million by selling 5,747,118 series A convertible redeemable preferred shares in a...[More...]

Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results

Fri, 14 Aug 2009 18:49:00 GMT

Participated in the April 2009 61st PHARMCHINA in Zhengzhou, China, one
Revenues for the second quarter of 2009 decreased 30% to $13.6 million from $19.4 million of the same period of 2008.
Gross margins for the second quarter of 2009 increased to 57.9% as compared to 50.0% in the second quarter of 2008.

[More...]

Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results

Fri, 14 Aug 2009 15:55:00 GMT

Participated in the April 2009 61st PHARMCHINA in Zhengzhou, China, one
Revenues for the second quarter of 2009 decreased 30% to $13.6 million from $19.4 million of the same period of 2008.
Wholesale revenues, one of the revenue segments, accounting for 78% of total revenues, decreased 25% due to the Company's 2009 product pricing policy(1).

[More...]

Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets

Thu, 30 Jul 2009 11:57:00 GMT

Lotus Pharmaceuticals, Inc. a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported it received notice of patent pending from the State Intellectual Property Office of the People's Republic of China for its innovative patent application of Gliclazide-Controlled Release Tablets submitted in 2008. Meanwhile, Gliclazide-Controlled Release Tablets has undergone pre-clinical evaluation approved by the State Food and Drug Administration in 2009.[More...]

Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification

Mon, 29 Jun 2009 15:01:00 GMT

Lotus Pharmaceuticals, Inc. a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported it received a Good Supply Practices certificate from the Chinese State Food & Drug Administration for the second time since 2003.[More...]

Lotus Pharmaceuticals, Inc. To Exhibit at the 2009 International Conference for Bioeconomy

Wed, 17 Jun 2009 15:46:00 GMT

About the 2009 International Conference for Bioeconomy-the 44th New Drugs Expo
The 2009 International Conference for Bioeconomy, sponsored by Ministry of Science and Technology, State Food and Drug Administration, and the Tianjin Municipal Government, is aimed to tackle financial crisis with the development of bio-economy.
It is one of the largest and most reputable biotech and new drugs conferences in China.

[More...]

Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results

Mon, 18 May 2009 17:48:00 GMT

First Quarter 2009 Highlights and Recent Developments:
Revenues for the first quarter of 2009 increased 1% to $11.8 million, up from $11.7 million in the first quarter of 2008.
Both wholesale revenues (76% of total net revenues for the first quarter of 2009) and retail revenues (18% of total net revenues for the first quarter of 2009) increased 6%, but other revenues (6% of total revenues for the first quarter of 2009) decreased 41% for the first quarter of 2009 as compared to the first quarter of 2008.

[More...]

Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug

Wed, 18 Feb 2009 16:00:00 GMT

Lotus Pharmaceuticals, Inc. , a company that controls and operates pharmaceutical companies in the People's Republic of China , today announced that contractually controlled Beijing Liang Fang Pharmaceutical Co., Ltd. entered into an intellectual rights transfer contract with Beijing Yipuan Bio-Medical Technology Co., Ltd. in December 2008 to acquire the drug Yipubishan, a highly effective and stable octreotide acetate injection solution, according to a clinical research report issued by Beijing Union Medical College Hospital Center for Clinical Pharmacology, used to treat the symptoms of gastric ulcers and hemorrhages of the upper digestive tract since 2004.[More...]

Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs

Thu, 05 Feb 2009 12:57:00 GMT

Lotus Pharmaceuticals, Inc. , a pharmaceutical products developer, manufacturer and distributor in the People's Republic of China, today announced that its contractually controlled subsidiary Beijing Liang Fang Pharmaceutical Co., Ltd. completed paying RMB180 million in December 2008 for land use rights to property in the Chahaer Industrial Park, located in Inner Mongolia. This was an important step towards achieving the Company's long term growth plans.[More...]

Lotus Pharmaceuticals Announces Third Quarter 2008 Results

Tue, 18 Nov 2008 10:55:00 GMT

Lotus Pharmaceuticals, Inc. , a company that controls and operates pharmaceutical companies in the People's Republic of China , today announced financial results for the quarter and nine months ended September 30, 2008.[More...]

Lotus Pharmaceuticals Announces Conference Call to Discuss Third Quarter 2008 Results

Fri, 14 Nov 2008 20:32:00 GMT

Lotus Pharmaceuticals, Inc. , a pharmaceutical company in the People's Republic of China , today announced that it will conduct a conference call at 9:00 a.m. Eastern Standard Time on Tuesday, November 18, 2008 to discuss results for the quarter ended September 30, 2008.[More...]